Clinical Trial Update: Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II dose-escalation study evaluating TLC590 for postsurgical pain management in inguinal hernia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inguinal Hernia

Drugs mentioned

• TLC590

Snippet

Sponsor: Taiwan Liposome Company | Conditions: Inguinal Hernia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-14